potent, selective CECR2 bromodomain inh.

cell permeable tool compound

from HTS + SBDD on ATAD2, CECR2 model

J. Med. Chem., May 28, 2020

GlaxoSmithKline, Stevenage, UK

GSK232 is a highly selective cell-penetrant inhibitor of the non-BET CECR2 bromodomain with >500-fold selectivity over BET-family bromodomains identified during a campaign to find selective inhibitors of the bromodomain…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks